97202 ⎘
Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells Lung
CEACAM5 ANTIBODY-DRUG CONJUGATE FORMULATION
#2ANTI-MET ANTIBODIES, BISPECIFIC ANTIGEN BINDING MOLECULES THAT BIND MET, AND METHODS OF USE THEREOF
#3COMBINATION OF A PD-1 ANTAGONIST AND A VEGFR INHIBITOR FOR TREATING CANCER
#4ANTI-PD-L1 COMBINATIONS FOR TREATING TUMORS
#5METHODS OF TREATING CANCERS USING PD-1 AXIS BINDING ANTAGONISTS AND TAXANES
#6DOSAGES OF IMMUNOCONJUGATES OF ANTIBODIES AND SN-38 FOR IMPROVED EFFICACY AND DECREASED TOXICITY
#7BISPECIFIC FUSION PROTEIN USING ORTHOPOXVIRUS MAJOR HISTOCOMPATIBILITY COMPLEX (MHC) CLASS I-LIKE PROTEIN (OMCP) AND TUMOR-SPECIFIC BINDING PARTNER
#8Methods of Treating IL1RAP Associated Cancers with Anti Human Interleukin-1 Receptor Accessory Protein (IL1 RAP) Antibodies
#9ANTI-CANCER ANTIBODIES, COMBINATION THERAPIES, AND USES THEREOF
#10ANTI-TROP2 ANTIBODY-DRUG CONJUGATE
#11ANTI-MET ANTIBODIES, BISPECIFIC ANTIGEN BINDING MOLECULES THAT BIND MET, AND METHODS OF USE THEREOF
#12ANTI-DLL3 ANTIBODY
#13FGFR2 INHIBITORS ALONE OR IN COMBINATION WITH IMMUNE STIMULATING AGENTS IN CANCER TREATMENT
#14CONJUGATED ANTIBODIES AGAINST LY75 FOR THE TREATMENT OF CANCER
#15ANTI-EGFR ANTIBODIES AND ANTIBODY DRUG CONJUGATES
#16METHODS OF TREATING CANCERS USING PD-1 AXIS BINDING ANTAGONISTS AND TAXANES
#17USE OF ANTI-PD-1 ANTIBODY IN COMBINATION WITH ANTI-CD27 ANTIBODY IN CANCER TREATMENT
#18BETA-GLUCAN IN COMBINATION WITH ANTI-CANCER AGENTS AFFECTING THE TUMOR MICRENVIRONMENT
#19BETA-GLUCAN METHODS AND COMPOSITIONS THAT AFFECT THE TUMOR MICROENVIRONMENT
#20COMPOUND THAT SPECIFICALLY BINDS TO KIR3DL2 FOR USE IN THE TREATMENT OF PERIPHERAL T CELL LYMPHOMA
#21METHODS OF TREATING CANCERS USING PD-1 AXIS BINDING ANTAGONISTS AND TAXANES
#22DLL3 BINDING MOLECULES AND USES THEREOF
#23CHIMERIC ANTIGEN RECEPTOR T CELL AND CONSTRUCTION METHOD THEREOF, AND ANTITUMOR DRUG
#24TREATMENT OF LUNG CANCER USING A COMBINATION OF AN ANTI-PD-1 ANTIBODY AND ANOTHER ANTI-CANCER AGENT
#25PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST CANCERS
#26GRP78-BINDING ANTIBODIES AND USE THEREOF IN DETECTING OR NEUTRALIZING GRP78
#27USE OF ANTI-PD-1 ANTIBODY IN COMBINATION WITH ANTI-CD27 ANTIBODY IN CANCER TREATMENT
#28BETA-GLUCAN IN COMBINATION WITH ANTI-CANCER AGENTS AFFECTING THE TUMOR MICROENVIRONMENT
#29ANTIBODY MOLECULES TO PG-L1 AND METHODS OF TREATING CANCER AND INFECTIOUS DISEASES
#30METHODS OF TREATING CANCERS USING PD-1 AXIS BINDING ANTAGONISTS AND TAXANES
#31ANTIBODIES AGAINST CLAUDIN 18.2 USEFUL IN CANCER DIAGNOSIS
#32ANTIBODY-UREASE CONJUGATES FOR THERAPEUTIC PURPOSES
#33B7H4-TARGETED ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF
#34METHODS FOR TREATING CANCER
#35THERAPY FOR METASTATIC UROTHELIAL CANCER WITH THE ANTIBODY-DRUG CONJUGATE, SACITUZUMAB GOVITECAN (IMMU-132)
#36METHODS OF TREATING CANCER USING PD-1 AXIS BINDING ANTAGONISTS AND TIGIT INHIBITORS
#37VISTA Antagonist and Methods of Use
#38ANTI-B7-H1 ANTIBODIES FOR TREATING TUMORS
#39METHODS AND COMPOSITIONS FOR ENHANCING THE POTENCY OF SUPERANTIGEN MEDIATED CANCER IMMUNOTHERAPY
#40COMPOSITIONS COMPRISING A COMBINATION OF AN ANTI-PD-1 ANTIBODY AND ANOTHER ANTIBODY
#41COMBINATION THERAPY WITH IMMUNE CELL ENGAGING PROTEINS AND IMMUNOMODULATORS
#42CANCER THERAPY USING CLDN6 TARGET-DIRECTED ANTIBODIES IN VIVO
#43METHODS OF TREATING CANCERS USING PD-1 AXIS BINDING ANTAGONISTS AND TAXANES
#44COMBINATION THERAPIES
#45ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 158P1D7 PROTEINS
#46METHOD OF TREATING CANCER COMPRISING ADMINISTRATION OF ANTI-HER2 ANTIBODY-DRUG CONJUGATE
#47CAR Cells and Polyspecific Binding Molecules for Treating Solid Tumor
#48UNGULATE-DERIVED POLYCLONAL IMMUNOGLOBULIN SPECIFIC FOR EGFR AND USES THEREOF
#49ANTI-MET ANTIBODIES, BISPECIFIC ANTIGEN BINDING MOLECULES THAT BIND MET, AND METHODS OF USE THEREOF
#50Anti-AXL Antagonistic Antibodies
#51CHIMERIC ANTIGEN RECEPTOR COMPRISING AN ANTIGEN BINDING DOMAIN SPECIFIC FOR MSLN HAVING A SPECIFICITY FOR TUMOR CELLS
#52ANTIBODIES AGAINST OX-40 AND USES THEREOF
#53ANTI-DLL3 ANTIBODIES AND METHODS OF USE
#54Peptides for use in immunotherapy against cancers
#55NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST OVARIAN CANCER AND OTHER CANCERS
#56DIAGNOSTIC ASSAYS AND KITS FOR DETECTION OF FOLATE RECEPTOR 1
#57METHODS OF TREATING CANCERS USING PD-1 AXIS BINDING ANTAGONISTS AND TAXANES
#58METHODS FOR TREATING CANCER
#59IMMUNOACTIVATING ANTIGEN-BINDING MOLECULE
#60Phage-displayed accessible recombinant targeted antibodies and methods of making same
#61FGFR2 INHIBITORS ALONE OR IN COMBINATION WITH IMMUNE STIMULATING AGENTS IN CANCER TREATMENT
#62ANTIBODIES AGAINST CD73 AND USES THEREOF
#63GRP78-binding antibodies and uses thereof in detecting or neutralizing GRP78
#64Bispecific Fusion Protein Using Orthopoxvirus Major Histocompatibility Complex (MHC) Class I-Like Protein (OMCP) and Tumor-Specific Binding Partner
#65COMPOSITIONS AND METHODS FOR TCR REPROGRAMMING USING FUSION PROTEINS
#66GRP78-binding antibodies and uses thereof in detecting or neutralizing GRP78
#67ANTI CANCER COMBINATION THERAPY
#68COMBINATION OF A PD-1 ANTAGONIST AND A VEGFR INHIBITOR FOR TREATING CANCER
#69METHODS OF TREATING CANCERS USING PD-1 AXIS BINDING ANTAGONISTS AND TAXANES
#70GRP78-binding antibodies and uses thereof and selection of phage-displayed accessible recombinant targeted antibodies
#71ANTI-EGFR ANTIBODIES AND ANTIBODY DRUG CONJUGATES
#72PROTEINS COMPRISING BINDING REGIONS, SHIGA TOXIN A SUBUNIT EFFECTOR REGIONS, AND CARBOXY-TERMINAL, ENDOPLASMIC RETICULUM LOCALIZATION SIGNAL MOTIFS
#73Bispecific antigen-binding construct and preparation method and use thereof
#74ANTI-PD-L1 COMBINATIONS FOR TREATING TUMORS
#75PROVASOPRESSIN ANTAGONISTS AND USES THEREOF
#76B7H4-targeted antibody-drug conjugates and methods of use thereof
#77COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF TUMOR
#78CEACAM5 ANTIBODY-DRUG CONJUGATE FORMULATION
#79COMBINED PHARMACEUTICAL COMPOSITION
#80Marker composition for diagnosing or predicting prognosis of lung cancer based on exosome overexpressing GCC2 gene or protein
#81THERAPEUTIC ANTIBODIES FOR TREATING LUNG CANCER
#82COMBINED PHARMACEUTICAL COMPOSITION
#83TREATMENT OF LUNG CANCER USING AN ANTI-FUCOSYL-GM1 ANTIBODY
#84ANTI-VISTA ANTIBODIES AND FRAGMENTS
#85Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
#86Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
#87ANTI-OX40 ANTIBODIES AND THEIR USES
#88Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
#89Anti Human Interleukin-1 Receptor Accessory Protein (IL1 RAP) Antibodies and Uses Thereof
#90NOVEL CANCER ANTIGENS AND ANTIBODIES OF SAID ANTIGENS
#91REMOVAL OF TARGET CELLS BY CIRCULATING VIRUS-SPECIFIC CYTOTOXIC T-CELLS USING MHC CLASS I COMPRISING COMPLEXES
#92USE OF ANTI-CEACAM5 IMMUNOCONJUGATES FOR TREATING LUNG CANCER
#93ICOS BINDING PROTEINS
#94Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
#95Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
#96ANTIBODIES AGAINST THE MUC1-C/EXTRACELLULAR DOMAIN (MUC1-C/ECD)
#97ANTI-MET ANTIBODIES, BISPECIFIC ANTIGEN BINDING MOLECULES THAT BIND MET, AND METHODS OF USE THEREOF
#98Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
#99BETA-GLUCAN IN COMBINATION WITH ANTI-CANCER AGENTS AFFECTING THE TUMOR MICROENVIRONMENT
#100METHODS OF TREATING CANCERS USING PD-1 AXIS BINDING ANTAGONISTS AND TAXANES
#101THERAPY FOR METASTATIC UROTHELIAL CANCER WITH THE ANTIBODY-DRUG CONJUGATE, SACITUZUMAB GOVITECAN (IMMU-132)
#102ANTI-DLL3 ANTIBODY
#103CONJUGATED ANTIBOIDES AGAINST LY75 FOR THE TREATMENT OF CANCER
#104Compound that specifically binds to KIR3DL2 for use in the treatment of peripheral T cell lymphoma
#105ANTI-HER2 BIPARATOPIC ANTIBODY-DRUG CONJUGATES AND METHODS OF USE
#106METHODS OF TREATING CANCER USING PD-1 AXIS BINDING ANTAGONISTS AND TIGIT INHIBITORS
#107Peptides for use in immunotherapy against cancers
#108Peptides for use in immunotherapy against cancers
#109METHODS OF TREATING CANCER USING PD-1 AXIS BINDING ANTAGONISTS AND TIGIT INHIBITORS
#110TREATMENT OF LUNG CANCER USING A COMBINATION OF AN ANTI-PD-1 ANTIBODY AND ANOTHER ANTI-CANCER AGENT
#111NAPI2B-TARGETED ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF
#112ANTIBODY MOLECULES TO PD-L1 AND USES THEREOF
#113BETA-GLUCAN METHODS AND COMPOSITIONS THAT AFFECT THE TUMOR MICROENVIRONMENT
#114TARGETED THERAPY FOR SMALL CELL LUNG CANCER
#115Epitope specific antibodies that bind cell surface GRP78 and their use for cancer detection
#116Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
#117VISTA Antagonist and Methods of Use
#118ANTI-TROP2 ANTIBODY-DRUG CONJUGATE
#119METHODS OF TREATING CANCERS USING PD-1 AXIS BINDING ANTAGONISTS AND TAXANES
#120ANTI-PD-1 ANTIBODIES, ACTIVATABLE ANTI-PD-1 ANTIBODIES, AND METHODS OF USE THEREOF
#121Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
#122Anti-B7-H1 antibodies for treating tumors
#123Anti-EGFRvIII antibodies and uses thereof
#124Use of anti-PD-1 antibody in combination with anti-CD27 antibody in cancer treatment
#125Antibody drug conjugates (ADC) that bind to 158P1D7 proteins
#126Combination therapy of T cell activating bispecific antigen binding molecules and PD-1 axis binding antagonists
#127MPS PEPTIDES AND USE THEREOF
#128Compositions and methods for treating lung cancer
#129THERAPEUTIC AND DIAGNOSTIC TARGET FOR CANCER COMPRISING DLL3 BINDING REAGENTS
#130CANCER THERAPY USING CLDN6 TARGET-DIRECTED ANTIBODIES IN VIVO
#131ANTI-OX40 ANTIBODIES AND THEIR USES
#132Periostin antibodies and methods of using the same
#133ANTI-OX40 ANTIBODIES AND METHODS OF USE
#134COMBINATION THERAPIES
#135ANTI-EGFR ANTIBODIES AND ANTIBODY DRUG CONJUGATES
#136Antibodies against OX-40 and uses thereof
#137METHODS OF TREATING CANCER USING PD-1 AXIS BINDING ANTAGONISTS AND TIGIT INHIBITORS
#138METHODS OF TREATING CANCERS USING PD-1 AXIS BINDING ANTAGONISTS AND TAXANES
#139Antibodies to human B7x for treatment of metastatic cancer
#140Method of treating cancer comprising administration of anti-HER2 antibody-drug conjugate
#141SITE SPECIFIC HER2 ANTIBODY DRUG CONJUGATES
#142CHIMERIC ANTIGEN RECEPTOR, NKG2D CAR-NK CELLS EXPRESSING THE CHIMERIC ANTIGEN RECEPTOR, AND PREPARATION AND APPLICATION THEREOF
#143Methods of producing an IL-1 RAP antibodies
#144METHODS FOR B CELL PRECONDITIONING IN CAR THERAPY
#145Diagnostic Assays and Kits for Detection of Folate Receptor 1
#146COMBINATION OF A PD-1 ANTAGONIST AND A VEGFR INHIBITOR FOR TREATING CANCER
#147Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
#148Bispecific antigen-binding construct and preparation method and use thereof
#149Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
#150Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
#151Anti-ErbB3 antibodies and uses thereof
#152BISPECIFIC ANTIBODIES AGAINST CD3EPSILON AND ROR1
#153Combination therapy comprising nivolumab and ipilimumab
#154ANTI-OX40 ANTIBODIES AND THEIR USES
#155ANTI-CD22 ANTIGEN BINDING MOLECULES TO TREAT LUNG CANCER AND PROSTATE CANCER
#156REMOVAL OF TARGET CELLS BY CIRCULATING VIRUS-SPECIFIC CYTOTOXIC T-CELLS USING MHC CLASS I COMPRISING COMPLEXES
#157ICOS BINDING PROTEINS
#158Antibodies that bind cell surface GRP78
#159Light chain variable regions
#160METHODS OF TREATING CANCERS USING PD-1 AXIS BINDING ANTAGONISTS AND TAXANES
#161METHODS FOR TREATING CANCER
#162ICOS binding proteins
#163Anti-HER2 biparatopic antibody-drug conjugates and methods of use
#164Compositions and methods for detecting lung cancer
#165Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
#166Methods and compositions for enhancing the potency of superantigen mediated cancer immunotherapy
#167Methods and compositions for enhancing the potency of superantigen mediated cancer immunotherapy
#168ANTIBODIES TO NON-FUNCTIONAL P2X7 RECEPTOR
#169Anti-OX40 antibodies and their uses
#170Anti-vista antibodies and fragments
#171TREATMENT OF LUNG CANCER USING AN ANTI-FUCOSYL-GM1 ANTIBODY
#172Therapy for metastatic urothelial cancer with the antibody-drug conjugate, sacituzumab govitecan (IMMU-132)
#173Peptides for use in immunotherapy against cancers
#174Anti-B7-H1 antibodies for treating tumors
#175TUMOR TARGETING CONJUGATES AND METHODS OF USE THEREOF
#176ANTI-PD-L1 MONOCLONAL ANTIBODIES AND FRAGMENTS THEREOF
#177Antibody or antibody fragment capable of binding to lung-specific X protein and use thereof
#178ANTI-IL1RAP ANTIBODIES, BISPECIFIC ANTIGEN BINDING MOLECULES THAT BIND IL1RAP AND CD3, AND USES THEREOF
#179COMBINATION OF A PD-1 ANTAGONIST AND AN IDO1 INHIBITOR FOR TREATING CANCER
#180Re-directed immunotherapy
#181Interferon Therapy
#182Combination of ABCG2 inhibitors with sacituzumab govitecan (IMMU-132) overcomes resistance to SN-38 in Trop-2 expressing cancers
#183DLL3 MODULATORS AND METHODS OF USE
#184COMBINATION THERAPY FOR CANCER
#185Diagnostic assays and kits for detection of folate receptor 1
#186Anti human interleukin-1 receptor accessory protein (IL1 RAP) antibodies and uses thereof
#187EphA5-binding antibodies and uses thereof and selection of phage-displayed accessible recombinant targeted antibodies
#188ANTIBODIES FOR EPIDERMAL GROWTH FACTOR RECEPTOR 3 (HER3)
#189Targeting CLPTM1L for treatment and prevention of cancer
#190COMPOSITIONS AND METHODS FOR TREATMENT AND DETECTION OF CANCERS
#191Anti-Axl antagonistic antibodies
#192Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
#193Antibodies specific to Sonic Hedgehog and method of use thereof
#194Antibody binding to carbonic anhydrase and use thereof
#195Anti-HER3 antibody-drug conjugate
#196Anti-TROP2 antibody-drug conjugate
#197ANTI-EGFR ANTIBODIES AND ANTIBODY DRUG CONJUGATES
#198Compound that specifically binds to KIR3DL2 for use in the treatment of peripheral T cell lymphoma
#199High-affinity anti-human folate receptor beta antibodies and methods of use
#200ANTI-MESOTHELIN ANTIBODIES
#201Antibody-drug conjugates containing anti-Globo H antibodies and uses thereof
#202CONJUGATED ANTIBODIES AGAINST LY75 FOR THE TREATMENT OF CANCER
#203Antibody-drug conjugates and immunotoxins
#204NUCLEIC ACID AND CORRESPONDING PROTEIN ENTITLED 161P2F10B USEFUL IN TREATMENT AND DETECTION OF CANCER
#205Multispecific fab fusion proteins and use thereof
#206Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
#207Composition for regulating cell division comprising FCHO1 modulator, and method for regulating cell division using same
#208Dual function antibodies specific to glycosylated PD-L1 and methods of use thereof
#209Efficacy of anti-HLA-DR antibody drug conjugate IMMU-140 (hL243-CL2A-SN-38) in HLA-DR positive cancers
#210Method for treating cancer comprising administration of anti-HER2 antibody-drug conjugate
#211NOVEL ANTI-CLAUDIN ANTIBODIES AND METHODS OF USE
#212Antibodies against CD73 and uses thereof
#213COMBINATION THERAPY COMPRISING ANTI-ANGIOGENESIS AGENTS AND OX40 BINDING AGONISTS
#214Antigen binding proteins that bind CCR2
#215Compositions and Methods for Diagnosing and Treating Cancer
#216BETA-GLUCAN IN COMBINATION WITH ANTI-CANCER AGENTS AFFECTING THE TUMOR MICROENVIRONMENT
#217BETA-GLUCAN METHODS AND COMPOSITIONS THAT AFFECT THE TUMOR MICROENVIRONMENT
#218ANTI-PD-L1 COMBINATIONS FOR TREATING TUMORS
#219DLL3 MODULATORS AND METHODS OF USE
#220Binding molecules specific for HER3 and uses thereof
#221Prostate-associated antigens and vaccine-based immunotherapy regimens
#222THERAPEUTIC DRUG FOR MALIGNANT TUMORS
#223Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
#224Antibodies specific for Trop-2 and their uses
#225ANTI-OX40 ANTIBODIES AND THEIR USES
#226Anti-PD-L1 combinations for treating tumors
#227Anti-cancer combination therapy
#228Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
#229ICOS BINDING PROTEINS
#230METHODS FOR B CELL PRECONDITIONING IN CAR THERAPY
#231Antibodies against claudin 18.2 useful in cancer diagnosis
#232Anti-DLL3 antibody drug conjugates for treating cancer
#233Antibodies against the MUC1-C/extracellular domain (MUC1-C/ECD)
#234Anti-EGFRvIII antibodies and uses thereof
#235COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF TUMOR
#236Antibody drug conjugates (ADC) that bind to 158P1D7 proteins
#237Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
#238Recombinant human IgM-antibody effective against cancer cells
#239VISTA Agonist and Methods of Use
#240Sialyl-di-Lewisas expressed on glycoproteins but not glycolipids as a functional cancer target and antibodies thereto
#241Anti-OX40 antibodies and methods of use
#242Antibodies to endoplasmin and their use
#243Combined use of anti PD-1 and anti M-CSF antibodies in the treatment of cancer
#244Methods for enhancing anti-tumor antibody therapy
#245THERAPEUTIC AND DIAGNOSTIC TARGET FOR CANCER COMPRISING DLL3 BINDING REAGENTS
#246Anti-OX40 antibodies and their uses
#247Antibody molecules to PD-L1 and methods of treating cancer
#248Therapy of small-cell lung cancer (SCLC) with a topoisomerase-I inhibiting antibody-drug conjugate (ADC) targeting Trop-2
#249LIGAND-CYTOTOXIC DRUG CONJUGATE, PREPARATION METHOD THEREOF, AND USE THEREOF
#250Anti-OX40 antibodies and their uses
#251TREATMENT OF PD-L1 POSITIVE LUNG CANCER USING AN ANTI-PD-1 ANTIBODY
#252Masking chimeric antigen receptor T cells for tumor-specific activation
#253Cancer therapy using CLDN6 target-directed antibodies in vivo
#254ANTI-LAMP1 ANTIBODIES AND ANTIBODY DRUG CONJUGATES, AND USES THEREOF
#255Anti-MET antibodies, bispecific antigen binding molecules that bind MET, and methods of use thereof
#256Antibodies reactive with B7-H3 and users thereof
#257Anti-EGFR antibodies and antibody drug conjugates
#258Anti-c-Met antibody and anti-c-Met antibody-cytotoxic drug conjugate and pharmaceutical use thereof
#259Therapy for metastatic urothelial cancer with the antibody-drug conjugate, sacituzumab govitecan (IMMU-132)
#260Anti-TROP2 antibody-drug conjugate
#261ANTIBODIES THAT BIND CELL SURFACE GRP78 AND THEIR USE FOR DETECTION OF CANCER
#262Lung cancer diagnosis marker, antibody and application thereof
#263Methods for treatment of cancer with therapeutic combinations comprising PEG-IL-10
#264NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST OVARIAN CANCER AND OTHER CANCERS
#265CKAP4-molecular-targeted antitumor agent
#266Methods of delivering DLL3 antibody drug conjugates
#267Methods of making DLL3 antibody drug conjugates
#268Anti-ErbB3 antibodies and uses thereof
#269Anti-DLL3 antibody drug conjugates and methods of use
#270Anti-Ly6E antibodies and immunoconjugates and methods of use
#271Diagnostic assays and kits for detection of folate receptor 1
#272Methods of treating cancer using anti human interleukin-1 receptor accessory protein (IL1 RAP) antibodies
#273Antibody-urease conjugates for therapeutic purposes
#274Anti-DLL3 antibody drug conjugates
#275Use of anti-PD-1 antibody in combination with anti-CD27 antibody in cancer treatment
#276Efficacy of anti-HLA-DR antiboddy drug conjugate IMMU-140 (hL243-CL2A-SN-38) in HLA-DR positive cancers
#277Combination therapy of T cell activating bispecific antigen binding molecules and PD-1 axis binding antagonists
#278Anti-Axl antagonistic antibodies
#279Antibody binding to carbonic anhydrase and use thereof
#280Methods of treating conditions with antibodies that bind B7-H4
#281Polypeptide immunogen for generating an antibody to non-functional P2X7 receptor
#282Genetic products differentially expressed in tumors and the use thereof
#283Efficacy of anti-trop-2-SN-38 antibody drug conjugates for therapy of tumors relapsed/refractory to checkpoint inhibitors
#284Kits containing DLL3 antibody drug conjugates
#285Platform for the identification of tumor-associated cancer/testes antigens
#286Antibodies against OX40 and uses thereof
#287RSPO BINDING AGENTS AND USES THEREOF
#288Antibodies to GRP78
#289Compound that specifically binds to KIR3DL2 for use in the treatment of peripheral T cell lymphoma
#290Combination therapies
#291Lung cancer differential marker
#292COMBINATION THERAPIES OF ALK INHIBITORS
#293Anti-DLL3 antibody drug conjugates
#294Biomarker profiles for predicting outcomes of cancer therapy with ERBB3 inhibitors and/or chemotherapies
#295Composition for preventing or treating lung cancer comprising antibody against CD66C and chemotherapeutic agent
#296Anti-DLL3 antibody drug conjugates for treating cancer
#297Methods of making DLL3 antibody drug conjugates
#298Methods of delivering DLL3 antibody drug conjugates
#299Anti-DLL3 antibody drug conjugates
#300NaPi2b-targeted antibody-drug conjugates and methods of use thereof